IMMUNOMEDICS Aktie

2,70 EUR 2,9389%

Zu Ihrem Onlinebroker

kaufen verkaufen

IMMUNOMEDICS Aktienkurs : 25.05. ( 15 Min. verzögert)
2,70 € Letzter Kurs	2,94% Veränderung	2,62 € Vortag	2,62 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
2,70 - 2,62 Tag	3,04 - 2,09 52 Wochen	0 Tag	6 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

IMMUNOMEDICS Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

25.05.

Immunomedics to Present Final Results of Pancreatic Cancer Study With ...

MORRIS PLAINS, NJ, May 25, 2012 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. (NASDAQ:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of...
19.05.

Will Anthera's PEARL Shine Or Sink?

(BMY) and Merck Serono SA, which is in a phase III clinical study; Epratuzumab, being developed by Immunomedics Inc. and UCB SA, which has just entered a phase III study and LY2127399, being developed by Eli Lilly, which...

12.05.

Oppenheimer Reaffirms Outperform Rating on Immunomedics Incorporated (IMMU)

Immunomedics Incorporated (NASDAQ: IMMU)'s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer (NYSE: OPY) in a report released on Friday. They currently have a $6.00…
12.05.

Oppenheimer Maintains Outperform Rating, $6 PT for Immunomedics

By Dwight Einhorn In a company update published earlier today, Oppenheimer Holdings maintained its Outperform rating and $6.00 price target for Immunomedics, Inc. (NASDAQ: IMMU). Oppenheimer went on to say “Immunomedics recently reported financial ...
10.05.

Immunomedics to Present at Bank of America Merrill Lynch 2012 Health Care ...

MORRIS PLAINS, NJ, May 10, 2012 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. (NASDAQ:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of...